{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-26-000007","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2026-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.695327+00:00","generated_at":"2026-05-16T11:38:27.867598+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Immunic appoints Nash as CEO of Gliomic subsidiary; updates Vitt's employment terms","bullets":["Duane Nash to serve as CEO and President of wholly-owned Gliomic Therapeutics effective Jan 1, 2026, with monthly salary of $33,987.","Daniel Vitt enters new employment agreement: $305,000 annual salary, 55% target bonus, 50% US working time, $50,000 housing reimbursement.","Vitt's Suspension Agreement with Immunic AG terminated; he will now devote 50% time to Immunic AG with €282,826.50 annual salary and variable remuneration.","Nash's prior Executive Chairman agreement expired Dec 31, 2025; he remains Board Chairman but receives no cash retainer during his Gliomic employment term."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-26-000007","json":"https://secwatch.observer/filing/0001193805-26-000007.json","markdown":"https://secwatch.observer/filing/0001193805-26-000007.md","text":"https://secwatch.observer/filing/0001193805-26-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000007/0001193805-26-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000007/e665087_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:38:27.867598+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}